<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157623</url>
  </required_header>
  <id_info>
    <org_study_id>CASE 2614</org_study_id>
    <nct_id>NCT02157623</nct_id>
    <nct_alias>NCT02258243</nct_alias>
  </id_info>
  <brief_title>Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome</brief_title>
  <official_title>Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Maytin, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DUSA Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will be testing whether aminolevulinate-based (Levulan™) Photodynamic&#xD;
      Therapy (PDT) shows effectiveness in the treatment and prevention of cutaneous basal cell&#xD;
      carcinoma (BCC) in Basal Cell Nevus Syndrome (BCNS) patients. Levulan™ PDT is an FDA-approved&#xD;
      method widely used currently for squamous precancers of the skin. The investigators&#xD;
      hypothesize that PDT will provide exceptional benefit in the BCNS population because PDT is&#xD;
      nonmutagenic, nonscarring, and can be safely repeated many times. Additionally, the study&#xD;
      will investigate whether there are any differences in tumor clearance between the Blu-U®&#xD;
      (blue lamp) and Aktilite™(red lamp) therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot intra-patient comparative study to evaluate the ability of cyclic&#xD;
      Photodynamic Therapy (PDT) using Red (635 nm) or Blue (400 nm) light with 5-Aminolevulinic&#xD;
      acid, to eliminate BCC skin cancers that occur in patients with Basal Cell Nevus Syndrome&#xD;
      (Gorlin-Goltz Syndrome).&#xD;
&#xD;
      Patients will receive 3 cycles of Red light and Blue light PDT treatments, for a total of 6&#xD;
      treatments, over a 4 month period. Cycles will be spaced 2 months apart. Each cycle consists&#xD;
      of a double course of PDT treatment with treatments spaced one week apart. Every subject will&#xD;
      be treated with two light sources, blue and red, according to randomized assignments made to&#xD;
      left side or right side of the body. There will be a final assessment visit at month 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">September 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients received a different treatment to each half of their body. First Levulan with red light PDT (to tumors on one side of the body), and then Levulan with blue light PDT (to tumors on the other side of the body), at six treatment visits.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Clearance Rate Following Red or Blue Light PDT</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of clearance of existing BCC tumors will be assessed in patients with BCNS, using clinical and photographic measurements. The endpoint will be assessed for tumors in a Red light treatment field and a Blue light treatment field in each patient, and compared (bilateral intrapatient comparison).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain During Illumination</measure>
    <time_frame>Maximum value reported during the illumination period</time_frame>
    <description>Pain reported by the patient, using a 0-10 Visual Analog Scale (VAS), where 0 is no pain and 10 is maximum pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Survey</measure>
    <time_frame>6 months</time_frame>
    <description>Overall patient satisfaction with the technique will be assessed using a simple survey:&#xD;
6 = extremely satisfied; 5 = very satisfied; 4 = somewhat satisfied; 3 = somewhat dissatisfied; 2 = very dissatisfied; 1 = extremely dissatisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Basal Cell Nevus Syndrome</condition>
  <arm_group>
    <arm_group_label>Red Light PDT and Blue Light PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levulan</intervention_name>
    <description>Levulan application followed by Red or Blue light PDT</description>
    <arm_group_label>Red Light PDT and Blue Light PDT</arm_group_label>
    <other_name>Levulan™</other_name>
    <other_name>Levulan® Kerastick® for Topical Solution</other_name>
    <other_name>5-aminolevulinic acid</other_name>
    <other_name>aminolevulinic acid HCL</other_name>
    <other_name>ALA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Red Light PDT</intervention_name>
    <description>Aktilite™ (red lamp) after Levulan application on lesions</description>
    <arm_group_label>Red Light PDT and Blue Light PDT</arm_group_label>
    <other_name>Aktilite™</other_name>
    <other_name>Red Lamp</other_name>
    <other_name>Red Light</other_name>
    <other_name>PDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blue Light PDT</intervention_name>
    <description>Blu-U® (blue lamp) after Levulan application on lesions</description>
    <arm_group_label>Red Light PDT and Blue Light PDT</arm_group_label>
    <other_name>Blu-U</other_name>
    <other_name>Blue Lamp</other_name>
    <other_name>Blue Light</other_name>
    <other_name>PDT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men, women, and children of any age or ethnic group who meet eligibility&#xD;
&#xD;
          -  Patients under 18 years of age must be accompanied and co-consented, by a parent or&#xD;
             legal guardian.&#xD;
&#xD;
          -  Patients must have a diagnosis of Basal Cell Nevus Syndrome (BCNS)&#xD;
&#xD;
          -  For diagnosis of BCNS, the patient must have either 2 major criteria, one major and&#xD;
             two minor criteria, or one major criterion plus molecular confirmation of a PTCH1 gene&#xD;
             mutation&#xD;
&#xD;
          -  Major criteria are:&#xD;
&#xD;
               -  (1) BCC prior to age 20 years, or excessive number of BCCs out of proportion to&#xD;
                  prior sun exposure and skin type&#xD;
&#xD;
               -  (2) keratocyst of the jaw prior to age 20&#xD;
&#xD;
               -  (3) palmar or plantar pitting&#xD;
&#xD;
               -  (4) lamellar calcification of the falx cerebri&#xD;
&#xD;
               -  (5) medulloblastoma&#xD;
&#xD;
               -  (6) first degree relative with BCNS&#xD;
&#xD;
          -  Minor criteria are:&#xD;
&#xD;
               -  (1) rib anomalies, or other specific skeletal malformations including&#xD;
                  kyphoscoliosis and short 4th metacarpals&#xD;
&#xD;
               -  (2) macrocephaly&#xD;
&#xD;
               -  (3) cleft/lip or palate;&#xD;
&#xD;
               -  (4) fibroma of the heart or ovary&#xD;
&#xD;
               -  (5) ocular abnormalities&#xD;
&#xD;
               -  (6) other rare abnormalities&#xD;
&#xD;
          -  At least two BCC tumors, preferably more, located in different body regions or located&#xD;
             greater than 10 cm apart in locations that can be reproducibly separated into red and&#xD;
             blue illumination fields&#xD;
&#xD;
          -  Female subjects are not pregnant or nursing or planning to become pregnant during the&#xD;
             study&#xD;
&#xD;
          -  Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, planning on getting pregnant or nursing&#xD;
&#xD;
          -  Currently participating in another clinical trial&#xD;
&#xD;
          -  Using any topical treatment for their BCC tumors, unless discontinued at least 1 month&#xD;
             prior&#xD;
&#xD;
          -  Currently being treated for other cancers with medical or radiation therapy&#xD;
&#xD;
          -  Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of&#xD;
             the study material&#xD;
&#xD;
          -  Patients with a history of a photosensitivity disease, including porphyria cutanea&#xD;
             tarda&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward V. Maytin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>May 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Edward Maytin, MD, PhD</investigator_full_name>
    <investigator_title>Staff</investigator_title>
  </responsible_party>
  <keyword>Basal Cell Nevus Syndrome</keyword>
  <keyword>Gorlin's Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Red Light/Blue Light Participants</title>
          <description>Subjects will receive Red Light PDT on one side of the body, and Blue Light PDT to the contralateral side.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">3 patients, each received red light on half of body and blue light on the contralateral side.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Red Light / Blue Light Participants</title>
          <description>Subject will be receive red light PDT on one side of the body, and blue light PDT to the contralateral side after Levulan application</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="33" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Clearance Rate Following Red or Blue Light PDT</title>
        <description>The rate of clearance of existing BCC tumors will be assessed in patients with BCNS, using clinical and photographic measurements. The endpoint will be assessed for tumors in a Red light treatment field and a Blue light treatment field in each patient, and compared (bilateral intrapatient comparison).</description>
        <time_frame>6 months</time_frame>
        <population>Three (3) patients with BCNS were enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Red Light Photodynamic Therapy</title>
            <description>One side of patient received red light PDT</description>
          </group>
          <group group_id="O2">
            <title>Blue Light Photodynamic Therapy</title>
            <description>The other side of the patient received blue light PDT</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Clearance Rate Following Red or Blue Light PDT</title>
          <description>The rate of clearance of existing BCC tumors will be assessed in patients with BCNS, using clinical and photographic measurements. The endpoint will be assessed for tumors in a Red light treatment field and a Blue light treatment field in each patient, and compared (bilateral intrapatient comparison).</description>
          <population>Three (3) patients with BCNS were enrolled.</population>
          <units>Percentage of tumors cleared</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Tumors</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Tumors</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="75" upper_limit="96"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain During Illumination</title>
        <description>Pain reported by the patient, using a 0-10 Visual Analog Scale (VAS), where 0 is no pain and 10 is maximum pain possible.</description>
        <time_frame>Maximum value reported during the illumination period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pain During Red Light</title>
            <description>Pain during red light illumination (on a 0-10 visual analog scale)</description>
          </group>
          <group group_id="O2">
            <title>Pain During Blue Light</title>
            <description>Pain during blue light illumination (on a 0-10 visual analog scale)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain During Illumination</title>
          <description>Pain reported by the patient, using a 0-10 Visual Analog Scale (VAS), where 0 is no pain and 10 is maximum pain possible.</description>
          <units>VAS score value</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.0"/>
                    <measurement group_id="O2" value="3.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Survey</title>
        <description>Overall patient satisfaction with the technique will be assessed using a simple survey:&#xD;
6 = extremely satisfied; 5 = very satisfied; 4 = somewhat satisfied; 3 = somewhat dissatisfied; 2 = very dissatisfied; 1 = extremely dissatisfied.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Red Light Treatment</title>
            <description>RATING SCALE: 6 = extremely satisfied; 5 = very satisfied; 4 = somewhat satisfied; 3 = somewhat dissatisfied; 2 = very dissatisfied; 1 = extremely dissatisfied.</description>
          </group>
          <group group_id="O2">
            <title>Blue Light Treatment</title>
            <description>1 to 6 satisfaction scale</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction Survey</title>
          <description>Overall patient satisfaction with the technique will be assessed using a simple survey:&#xD;
6 = extremely satisfied; 5 = very satisfied; 4 = somewhat satisfied; 3 = somewhat dissatisfied; 2 = very dissatisfied; 1 = extremely dissatisfied.</description>
          <units>Scores on the rating scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="O2" value="5.6" lower_limit="5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Red Light Photodynamic Therapy</title>
          <description>Subject will be randomized to right or left side and assigned side will be treated with red light PDT after Levulan application&#xD;
Levulan: Levulan application followed by Red or Blue light PDT on randomized treatment fields&#xD;
Red Light Photodynamic Therapy: Aktilite™ (red lamp) after Levulan application on randomized treatment field</description>
        </group>
        <group group_id="E2">
          <title>Blue Light Photodynamic Therapy</title>
          <description>Subject will be randomized to right or left side and assigned side will be treated with blue light PDT after Levulan application&#xD;
Levulan: Levulan application followed by Red or Blue light PDT on randomized treatment fields&#xD;
Blue Light Photodynamic Therapy: Blu-U® (blue lamp) after Levulan application on randomized treatment field</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Maytin, MD, PhD</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-6676</phone>
      <email>maytine@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

